ClinicalTrials.gg
CompletedNCT06229782Updated Jan 30, 2024

Orbital Artery Doppler Ultrasound in Brain Death

An interventional study of Orbital Doppler ultrasonography and Transcranial Doppler ultrasonography in Brain Death, sponsored by Korgün Ökmen. Completed at 1 site in Turkey. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-01-30.

Sponsored by Korgün Ökmen · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 6 years 11 months after the study started (first participant enrolled Jan 2017, registered Jan 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Brain death is the irreversible loss of all activity in the brain, brainstem, and cerebellum, the part of the central nervous system that remains inside the skull.

The clinical diagnosis of brain death should be supported by ancillary tests that provide information about cerebral blood flow or electrical activity in the brain. Some of the ancillary tests that evaluate cerebral blood flow include transcranial Doppler ultrasonography (TDUS), computed tomography (CT) angiography (CTA), and catheter-based cerebral angiography.

This study hypothesized that Orbital Doppler ultrasonography (ODUS) alone is more effective than TDUS in detecting intracranial blood flow in diagnosing brain death. To this end, the investigators examined the results of ODUS in patients diagnosed as brain dead who underwent CT angiography.

02

Conditions studied

  • Brain Death

Browse trials for

03

In context

Brain Death

74 studies on the registry are indexed under Brain Death; 10 are open to participants now.

This study's enrollment of 66 is below the median of 154 across 39 interventional studies indexed under Brain Death.

Browse Brain Death studies →

Lead sponsor

Korgün Ökmen is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • suspected brain death

Exclusion criteria

Exclusion Criteria:

  • eye surgery,
  • uncontrolled diabetes mellitus,
  • facial trauma,
  • hypothermia,
  • hypotension (systolic pressure \< 100 mm Hg)
  • endocrine-metabolic coma
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Other
    ODUS

    Orbital Doppler ultrasonography (ODUS) Patients in whom brain death was suspected and the diagnostic procedure was initiated underwent ODUS .ODUS were performed during the apnoea test and the first neurological examination. At the second neurological examination at 12 hours, ODUS were repeated.

    Diagnostic Test: Orbital Doppler ultrasonography · Diagnostic Test: Transcranial Doppler ultrasonography · Diagnostic Test: Computed Tomography Angiography

Interventions

  • Diagnostic testOrbital Doppler ultrasonography

    During measurement, Doppler settings were adjusted to detect low flow and the smallest available Doppler gate was used for all ODUS examinations. The imaging probe position for ODUS was used transversely and axially, and mean values were recorded. ODUS 10-18 MHz linear probe was used.

  • Diagnostic testTranscranial Doppler ultrasonography

    During the measurement, Doppler settings were adjusted to detect low flow, and the minor available Doppler gate was used for all TDUS examinations. For TDUS, a temporal window was used approximately 1 cm above the midpoint of the line joining the lateral palpebral fissure and the external auditory meatus. Transcranial Doppler ultrasonography ( TDUS) 3-5 MHz convex array probe was used.

  • Diagnostic testComputed Tomography Angiography

    Cranial Computed Tomography Angiography

06

What researchers measure

Primary outcomes

  1. ODUS

    Orbital artery Doppler ultrasound (ODUS) ODUS measurements: T1; when brain death testing started; T2; 12 hours after the first measurement, T3; before CT angiography, T4; after CT angiography Peak systolic velocity (PSV) cm/s , end-diastolic velocity (EDV) cm/s measurement results. The absence of diastolic flow, reverse diastolic flow (oscillatory flow), and resistive index \>1 were considered brain death.

    Time frame: 30 minutes

  2. Resistive index (RI)

    The resistive index (RI) is a calculated flow parameter in ultrasound, derived from the maximum, minimum, and mean Doppler frequency shifts during a defined cardiac cycle. Along with the pulsatility index (PI), it is typically used to assess the resistance in a pulsatile vascular system.resistive index \>1 were considered brain death. RI measurements: T1; when brain death testing started; T2; 12 hours after the first measurement, T3; before CT angiography, T4; after CT angiography . RI = (PSV - EDV) / PSV PSV = peak systolic velocity and EDV = end-diastolic velocity.

    Time frame: 30 minutes

Secondary outcomes

  1. Transcranial Doppler ultrasound (TDUS)

    Transcranial Doppler ultrasound (TDUS) ultrasonography involves the use of a low-frequency (≤2 MHz) transducer, placed on the scalp, to insonate the basal cerebral arteries through relatively thin bone windows and to measure the cerebral blood flow velocity (CBFV) normal flow: mean = 55cm/sec. mild: \> 120cm/sec. moderate: \> 160cm/sec. s

    Time frame: 30 minutes

  2. Cerebral blood flow (CTA)

    Transcranial Computed Tomography Angiography

    Time frame: 40 minutes

  3. Optic nerve diameter

    Optic nerve diameter (mm) Orbital artery Doppler was performed simultaneously with ultrasound. The imaging probe position was used transversely and axially and mean values were recorded.

    Time frame: 30 minutes

07

Study locations

1 site
  • University of Health Sciences,,Bursa Yuksek Ihtisas Training and Research Hospital,
    Bursa, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Jan 2022, 60 months.

Of 14 interventional studies with no phase under Brain Death, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2024
First posted
Jan 29, 2024
StartActual
Jan 11, 2017
Primary completionActual
Jan 25, 2022
CompletionActual
Jun 13, 2022
Last update
Jan 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06229782
Lead sponsor
Korgün Ökmen
Responsible party
Korgün Ökmen (Principal Investigator, Bursa Yüksek İhtisas Education and Research Hospital) — Sponsor-investigator
First posted
Jan 29, 2024
Start date
Jan 11, 2017
Primary completion
Jan 25, 2022
Completion
Jun 13, 2022
Last update
Jan 30, 2024

Study contacts

Korgün Ökmen
principal investigator · UNIVERSITY OF HEALTH SCIENCES BURSA YUKSEK IHTISAS TRAINING AND RESEARCH HOSPITAL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion